French firm zeroes in on LTS Lohmann buy; Gilead nabs expanded FDA use for Complera;

@FiercePharma:  Endo to Acquire Specialty Pharmaceutical Company NuPathe. Release | Follow @FiercePharma

@EricPFierce: Bloomberg says drugmakers may catch a break in Germany. More | Follow @EricPFierce

@CarlyHFierce: Sanofi signs on to sell Vivus ED drug in emerging markets. Friday's story | Follow @CarlyHFierce

> The French investment firm Wendel is said to be in the lead for an LTS Lohmann buyout, with price negotiations all that remain between it and the drug patch maker. Report

> Gilead Sciences ($GILD) won FDA approval to expand its HIV treatment Complera to patients who have previously been treated with other drugs. Report

> Nagoya University released a report denying that its researchers manipulated data on patients in a trial for Novartis' ($NVS) hypertension treatment Diovan. Report

> Still awaiting approval for its multiple sclerosis drug Lemtrada in the U.S., Sanofi's ($SNY) Genzyme unit won the nod from Health Canada on Friday. Report

> The German generics maker Stada said it would start producing drugs in Myanmar under a joint venture with a local company; the country will be supplied from Stada's Vietnamese manufacturing facilities in the meantime. Report

> Irish authorities approved Allegan, MI-based Perrigo's ($PRGO) acquisition of Elan ($ELN), with closing expected later this week. Report

> The Hungarian drugmaker Richter bought a 51% stake in Brazil's Next Pharma to develop and distribute its female healthcare products there. Report

Medical Device News

@FierceMedDev: Mindray climbs back from damage done on Twitter. Article | Follow @FierceMedDev

@MarkHFierce: Solta Medical, an aesthetic med device maker with sagging sales, will sell itself for $250M. Reorganization wasn't enough. Story | Follow @MarkHFierce

@MichaelGFierce: To deliver drugs, German engineers took a cue from some of the best swimmers in nature: sperm cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Here's what 21 tweets can do to your reputation: Mindray climbs back from damage done on Twitter. More | Follow @GalenMoore

> GE Healthcare plans 100 new products to address massive India growth. More

> Siemens becomes one of Pfizer's many companion diagnostics suitors. News

> FDA approves eNeura's brain-stimulation device to treat migraines. Report

Biotech News

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Why is it a CEO can't be fired or quit? Amarin's Joe Z "retires." joins a long list of biotech retirees who either jumped or were pushed. More | Follow @JohnCFierce

@DamianFierce: Genentech wrote a solid guide to some of the methodology used in the much-discussed I-SPY 2 studies. More from Genetech | Follow @DamianFierce

@EmilyMFierce: Booster of red blood cells synthesized for first time. Story via SciAm | Follow @EmilyMFierce

> Cubist bounces along with more promising PhIII antibiotic results. News

> AcelRx spikes on $250M deal for late-stage pain drug/device Zalviso. More

> CEO of troubled Amarin heads for the exit as FDA readies Vascepa decision. Article

> Agenus mounts a comeback on positive results for its brain cancer vaccine. Story

CRO News

> Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug. Story

> Quotient Clinical is the latest CRO snapped up by private equity. Report

> Belgian CRO Genae reaches into Switzerland for medical device work. News

> Bayer teams up with Texas' MD Anderson for cancer clinical trials. More

> Charles River shakes up its leadership to cut costs and boost sales. Article

> CROS NT names a new CEO amid its global push. Item

Biotech IT News

>  Twitter-driven stock furor prompts exchange to fine Medivir. More

> Court fines Boehringer $1M for 'gross inadequacy' of record keeping. News

> Merck turns to gamification to help Type 2 diabetics. Article

> Accelrys inks $50M Qumas takeover to continue deal-driven expansion. Report

> BGI is building a huge genome database to drive drug discovery. Story

> NIH names its first associate director of data science. Item

And Finally... Cornell engineers developed a smartphone app that can gauge people's cholesterol levels using blood-test strips. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.